G

Geron Corp
D

GERN

4.01000
USD
0.03
(0.75%)
Market Closed
Volume
142,969
EPS
-0
Div Yield
-
P/E
-11
Market Cap
2,417,210,208
Related Instruments
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.48 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.85 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.14 USD
    T
    TK
    -0.23000
    (-2.86%)
    7.80000 USD
    V
    VSTM
    -0.13500
    (-3.26%)
    4.00000 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    XOM
    XOM
    -1.220
    (-1.01%)
    121.92 USD
    More
News

Title: Geron Corp

Sector: Healthcare
Industry: Biotechnology
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.